| COOPERATION | Acquiring Co. intends to continue strategic development work with Patent Assignee |
| OBSERVATION'S | Selling Co. retains rights to the technology for applications in drug discovery and development, including synthesis of intermediates and APIs, up to and including pre-clinical development. The portfolio acquired includes nearly 150 intermediates and complex chiral compounds. New business opportunities gained range from pre-clinical to launched compounds and from chiral building blocks to downstream synthesis of active pharmaceutical ingredients. |
| UPDATE | 26.02.2003 |
| BUSINESS ACQUISITIONS | This data is not available for free |
| CUSTOMER |
include major, emerging and start-up pharma companies in North America, Europe and Japan. |
| FAX NUMBER | This data is not available for free |
| PATENT ASSIGNEE | This data is not available for free |
| PHONE NUMBER | This data is not available for free |
|
Want more information ? Interested in the hidden information ? Click here and do your request. |